Research programme: VEGF-B gene therapy - Zenyth Therapeutics

Drug Profile

Research programme: VEGF-B gene therapy - Zenyth Therapeutics

Alternative Names: AM-132

Latest Information Update: 19 Apr 2010

Price : $50

At a glance

  • Originator Zenyth Therapeutics
  • Class Gene therapies
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 01 Dec 2005 Amrad Corporation is now called Zenyth Therapeutics
  • 06 May 2005 AM 132 is available for licensing (
  • 06 May 2005 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top